This panel provides information on interacting drugs and their ADRs along with references
Interacting drug |
Toxicity |
Interaction Type |
Mechanism |
Reference |
Ephedrine (299-42-3) | Hypertension | Synergistic | COMT inhibitors may inhibit the normal metabolism of ephedrine | Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy
|
Epinephrine (51-43-4) | Heart Rate Increased | Synergistic | Tolcapone inhibit the enzyme catechol-O-methyl transferase (COMT), which is concerned with the metabolism of drugs such as adrenaline (epinephrine) | The effect of entacapone on disposition and hemodynamic effects of intravenous isoproterenol and epinephrine
|
Levodopa (59-92-7) | Dyskinesia | Synergistic | When levodopa is given with a dopa-decarboxylase inhibitor such as carbidopa or benserazide, COMT becomes the major enzyme for metabolising levodopa, so inhibiting COMT delays the breakdown of levodopa | Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
|
Levodopa (59-92-7) | Hallucinations | Synergistic | When levodopa is given with a dopa-decarboxylase inhibitor such as carbidopa or benserazide, COMT becomes the major enzyme for metabolising levodopa, so inhibiting COMT delays the breakdown of levodopa | Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
|
Levodopa (59-92-7) | Nausea | Synergistic | When levodopa is given with a dopa-decarboxylase inhibitor such as carbidopa or benserazide, COMT becomes the major enzyme for metabolising levodopa, so inhibiting COMT delays the breakdown of levodopa | Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
|
Levodopa (59-92-7) | Orthostatic Hypotension | Synergistic | When levodopa is given with a dopa-decarboxylase inhibitor such as carbidopa or benserazide, COMT becomes the major enzyme for metabolising levodopa, so inhibiting COMT delays the breakdown of levodopa | Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
|
Levodopa (59-92-7) | Vomiting | Synergistic | When levodopa is given with a dopa-decarboxylase inhibitor such as carbidopa or benserazide, COMT becomes the major enzyme for metabolising levodopa, so inhibiting COMT delays the breakdown of levodopa | Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
|